My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.140 UNCHANGED

Streaming Delayed Price Updated: 4:15 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week ↗

September 05, 2021

Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday...

Via Benzinga

ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting

September 01, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion

August 16, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent

July 27, 2021

From ImmunityBio, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

July 14, 2021

Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low....

Via Benzinga

ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19

July 14, 2021

From ImmunityBio, Inc.

Via Business Wire

Cramer Weighs In On Cloudflare, MP Materials And More ↗

July 08, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he should talk more about Cloudflare Inc (NYSE: NET) on the show because it has got a great security component...

Via Benzinga

ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients

June 28, 2021

From ImmunityBio, Inc.

Via Business Wire

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer

June 15, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

June 10, 2021

From ImmunityBio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 07, 2021

Gainers Atossa Therapeutics (NASDAQ:ATOS)...

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 08, 2021

Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

June 03, 2021

Gainers Adamis Pharmaceuticals (NASDAQ:ADMP

Via Benzinga

ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa

May 25, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference

May 24, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021

May 20, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors Patients ↗

May 17, 2021

ImmunityBio Inc (NASDAQ: IBRX) has received FDA authorization to conduct a Phase 1 study to evaluate the m-ceNK platform combined with Anktiva (N-803) in...

Via Benzinga

FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors

May 17, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients

May 04, 2021

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs

April 29, 2021

From ImmunityBio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 27, 2021

Gainers BioVie (NASDAQ:BIVI) shares rose 11.62% to $24.0 during Tuesday's after-market session. Today's trading volume for this security ended up closing at 27.3K shares,...

Via Benzinga

ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple Indications

April 22, 2021

From ImmunityBio, Inc.

Via Business Wire

Single Dose Of ImmunityBio's Dual Antigen COVID-19 Vaccine Induces Ten-Fold Increase In T-Cell Responses ↗

April 08, 2021

ImmunityBio Inc (NASDAQ: IBRX) has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants. Just...

Via Benzinga

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2

April 08, 2021

From ImmunityBio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 06, 2021

Gainers Second Sight Medical (NASDAQ:EYES) stock increased by 33.37% to $9.87 during Tuesday's regular session. As of 12:32 EST, this security is trading at a volume...

Via Benzinga

51 Biggest Movers From Yesterday ↗

April 07, 2021

Gainers UTime Limited (NASDAQ: UTME) shares jumped 875% to close at $39.00 on Tuesday after the company priced its IPO at $4 per share. Romeo Power, Inc. (NYSE: RMO) climbed 59.6...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.